Healthcare provider profile · identity verified

Allison Miller Borja, MD

Internal Medicine · RALEIGH, NC · NPI 1215058722

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	381	96
Rosuvastatin Calcium	Rosuvastatin Calcium	312	92
Amlodipine Besylate	Amlodipine Besylate	290	81
Atorvastatin Calcium	Atorvastatin Calcium	282	79
Losartan Potassium	Losartan Potassium	228	62
Lisinopril	Lisinopril	212	54
Hydrochlorothiazide	Hydrochlorothiazide	155	42
Sertraline Hcl	Sertraline Hcl	140	33
Pravastatin Sodium	Pravastatin Sodium	129	34
Carvedilol	Carvedilol	116	31
Omeprazole	Omeprazole	110	33
Metoprolol Succinate	Metoprolol Succinate	104	28
Metformin Hcl Er	Metformin Hcl	101	25
Gabapentin	Gabapentin	90	31
Escitalopram Oxalate	Escitalopram Oxalate	88	20
Alendronate Sodium	Alendronate Sodium	87	28
Ezetimibe	Ezetimibe	85	28
Ozempic	Semaglutide	75	11
Bupropion Xl	Bupropion Hcl	72	20
Synthroid	Levothyroxine Sodium	72	18
Trazodone Hcl	Trazodone Hcl	72	20
Pantoprazole Sodium	Pantoprazole Sodium	71	18
Duloxetine Hcl	Duloxetine Hcl	68	16
Potassium Chloride	Potassium Chloride	68	19
Metformin Hcl	Metformin Hcl	67	19
Mounjaro	Tirzepatide	64	13
Celecoxib	Celecoxib	62	19
Valsartan	Valsartan	50	12
Azelastine Hcl	Azelastine Hcl	40	16
Metoprolol Tartrate	Metoprolol Tartrate	40	11
Citalopram Hbr	Citalopram Hydrobromide	39	suppressed
Allopurinol	Allopurinol	37	suppressed
Famotidine	Famotidine	37	suppressed
Spironolactone	Spironolactone	35	12
Fluticasone Propionate	Fluticasone Propionate	32	suppressed
Simvastatin	Simvastatin	32	suppressed
Alprazolam	Alprazolam	31	11
Clopidogrel	Clopidogrel Bisulfate	31	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Furosemide	Furosemide	31	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	suppressed
Atenolol	Atenolol	30	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	29	13
Olmesartan Medoxomil	Olmesartan Medoxomil	28	suppressed
Telmisartan	Telmisartan	27	suppressed
Lovastatin	Lovastatin	26	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	suppressed
Valacyclovir	Valacyclovir Hcl	26	14
Tamsulosin Hcl	Tamsulosin Hcl	25	suppressed
Jardiance	Empagliflozin	24	suppressed
Eliquis	Apixaban	23	suppressed
Meloxicam	Meloxicam	23	suppressed
Lorazepam	Lorazepam	22	suppressed
Clonazepam	Clonazepam	21	suppressed
Pregabalin	Pregabalin	20	suppressed
Acyclovir	Acyclovir	19	suppressed
Benazepril Hcl	Benazepril Hcl	19	suppressed
Ramipril	Ramipril	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	11
Linzess	Linaclotide	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	14
Klor-Con M10	Potassium Chloride	16	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Propranolol Hcl Er	Propranolol Hcl	15	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	13
Donepezil Hcl	Donepezil Hcl	13	suppressed
Dutasteride	Dutasteride	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Doxepin Hcl	Doxepin Hcl	12	suppressed
Montelukast Sodium	Montelukast Sodium	12	suppressed
Nadolol	Nadolol	12	suppressed
Rizatriptan	Rizatriptan Benzoate	12	suppressed
Cefdinir	Cefdinir	11	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Nexletol	Bempedoic Acid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error